	US 12,409,224 B2
	Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia
Mark Eric Kohler, Denver, CO (US); Haley Simpson, Denver, CO (US); Catherine Danis, Denver, CO (US); Lillie Leach, Denver, CO (US); and Amanda Novak, Denver, CO (US)
Assigned to The Regents of the University of Colorado, a body corporate
Filed by The Regents of the University of Colorado, A Body Corporate, Denver, CO (US)
Filed on Apr. 7, 2025, as Appl. No. 19/171,465.
Application 19/171,465 is a continuation of application No. PCT/US2024/058938, filed on Dec. 6, 2024.
Claims priority of provisional application 63/610,215, filed on Dec. 14, 2023.
Prior Publication US 2025/0235535 A1, Jul. 24, 2025
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 40/11 (2025.01) [A61K 40/31 (2025.01); A61K 40/421 (2025.01); A61P 35/02 (2018.01); C07K 16/283 (2013.01); C12N 5/0636 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01)]

30 Claims

1. A polypeptide comprising:

a) a first domain comprising SEQ ID NO: 1;

b) a second domain comprising an amino acid sequence of SEQ ID NO: 4;

c) a third domain comprising an amino acid sequence of SEQ ID NO: 5;

d) a fourth domain comprising an amino acid sequence of SEQ ID NO: 6; and

e) a fifth domain comprising an amino acid sequence of SEQ ID NO: 7.